目的 觀察膠體酒石酸鉍膠囊聯(lián)合美沙拉秦治療潰瘍性結(jié)腸炎的臨床效果。方法 選擇2017年2月—2019年3月在鄭州大學(xué)附屬鄭州中心醫(yī)院治療的潰瘍性結(jié)腸炎患者79例，隨機(jī)分成對照組（40例）和治療組（39例）。對照組口服美沙拉秦腸溶片，1.5 g/次，3次/d。治療組在對照組的基礎(chǔ)上口服膠體酒石酸鉍膠囊，3粒/次，4次/d。兩組患者均連續(xù)治療4周。觀察兩組患者臨床療效，同時(shí)比較治療前后兩組患者白細(xì)胞介素-6（IL-6）、腫瘤壞死因子-α（TNF-α）、IL-10、一氧化氮（NO）、過氧化脂質(zhì)（LPO）和超氧化物歧化酶（SOD）水平，及臨床癥狀緩解時(shí)間和潰瘍性結(jié)腸炎活動(dòng)度指數(shù)（DAI）。結(jié)果 治療后，對照組臨床有效率72.40%，顯著低于治療組的92.31%，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后兩組患者IL-6、TNF-α、NO和LPO水平均顯著降低（P<0.05），而SOD和IL-10水平顯著升高（P<0.05）；且治療后治療組患者這些指標(biāo)水平明顯比對照組好。治療后，兩組患者DAI水平均顯著降低（P<0.05），且治療組明顯比對照組低（P<0.05）。治療后，治療組黏液膿血便緩解時(shí)間和腹瀉緩解時(shí)間明顯比對照組短（P<0.05）。結(jié)論 膠體酒石酸鉍聯(lián)合美沙拉秦治療潰瘍性結(jié)腸炎，可糾正促炎因子，緩解氧化應(yīng)激反應(yīng)，改善腹瀉等臨床癥狀。

Objective To observe the clinical effect of Colloidal Bismuth Tartrate Capsules combined with mesalazine in treatment of ulcerative colitis. Methods Patients (79 cases) with ulcerative colitis in Zhengzhou Central Hospital Affiliated of Zhengzhou University from February 2017 to March 2019 were randomly divided into control (40 cases) and treatment (39 cases) groups. Patients in the control group were po administered with Mesalazine Enteric-coated Tablets, 1.5 g/time, three times daily. Patients in the treatment group were po administered with Colloidal Bismuth Tartrate Capsules on the basis of the control group, 3 grains/time, four times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacy was evaluated, and the levels of IL-6, TNF-α, IL-10, NO, LPO and SOD, the relief time of clinical symptom and DAI in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 72.40%, which was significantly lower than 92.31% in the treatment group, and there were differences between two groups (P<0.05). After treatment, the levels of IL-6, TNF-α, NO, LPO in two groups were significantly decreased (P<0.05), but the levels of IL-10 and SOD were significantly increased (P<0.05), and these indexes in the treatment group were significantly better than those in the control group (P<0.05). After treatment, the DAI level in two groups was significantly decreased (P<0.05), and which in the treatment group were significantly lower than that in the control group (P<0.05). After treatment, the remission time of mucinous purulent bloody stool and diarrhea in the treatment group was significantly shorter than that in the control group (P<0.05). Conclusion Colloidal Bismuth Tartrate Capsules combined with mesalazine in treatment of ulcerative colitis can correct the imbalance of pro-inflammatory and anti-inflammatory factors, alleviate oxidative stress reactions, and improve clinical symptoms such as diarrhea.

R975

河南省高等學(xué)校重點(diǎn)科研項(xiàng)目（19A320079）